tagraxofusp 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
fusion proteins	5323	2055491-00-2

Description:

Molecule	Description
Synonyms: elzonris tagraxofusp tagraxofusp-erzs SL-401 DT388IL3 Molecule 129	Tagraxofusp-erzs is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

elzonris
tagraxofusp
tagraxofusp-erzs
SL-401
DT388IL3
Molecule 129

Tagraxofusp-erzs is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 2018	FDA	STEMLINE THERAPEEUTICS INC
Jan. 7, 2021	EMA	STEMLINE THERAPEUTICS B.V.

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Capillary leak syndrome	93.22	49.58	12	48	2188	63486774

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Capillary leak syndrome	322.60	55.26	48	306	2210	34954367

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Capillary leak syndrome	348.44	58.30	50	327	3875	79740136

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01XX67	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
FDA CS	M0005633	Cytotoxins
FDA EPC	N0000193862	Cytotoxin
FDA EPC	N0000193864	CD123 Interaction
FDA MoA	N0000193865	CD123 Interactions

Showing 1 to 5 of 5 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Blastic plasmacytoid dendritic cell neoplasm	indication	445105005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Elongation factor 2	Enzyme	P13639	EF2_HUMAN					UNKNOWN
Interleukin-3 receptor	Membrane receptor	P26951 P32927	IL3RA_HUMAN IL3RB_HUMAN	BINDING AGENT				UNKNOWN	DRUG LABEL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
017871	NDDF
10770	INN_ID
2109054	RXNORM
303404	MMSL
35833	MMSL
4038207	VANDF
4038208	VANDF
783435000	SNOMEDCT_US
783577002	SNOMEDCT_US
8ZHS5657EH	UNII

Showing 1 to 10 of 16 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Elzonris	HUMAN PRESCRIPTION DRUG LABEL	1	72187-0401	INJECTION, SOLUTION	1000 ug	INTRAVENOUS	BLA	27 sections
Elzonris	HUMAN PRESCRIPTION DRUG LABEL	1	72187-0401	INJECTION, SOLUTION	1000 ug	INTRAVENOUS	BLA	27 sections
Elzonris	HUMAN PRESCRIPTION DRUG LABEL	1	72187-0401	INJECTION, SOLUTION	1000 ug	INTRAVENOUS	BLA	27 sections

Showing 1 to 3 of 3 entries

Previous1Next